 This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinsons disease. Half of participants will receive the deferiprone to 15 mg kg twice daily morning and evening 30mg kg per day, while the other half will receive a placebo. The treatment lasts nine months. 